These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 30014799)
21. A systematic review of probiotics as a potential intervention to restore gut health in HIV infection. Wilson NL; Moneyham LD; Alexandrov AW J Assoc Nurses AIDS Care; 2013; 24(2):98-111. PubMed ID: 22853885 [TBL] [Abstract][Full Text] [Related]
22. Molecular insights into probiotic mechanisms of action employed against intestinal pathogenic bacteria. van Zyl WF; Deane SM; Dicks LMT Gut Microbes; 2020 Nov; 12(1):1831339. PubMed ID: 33112695 [TBL] [Abstract][Full Text] [Related]
23. [Microbiota and gastrointestinal diseases]. Polanco Allué I An Pediatr (Barc); 2015 Dec; 83(6):443.e1-5. PubMed ID: 26534880 [TBL] [Abstract][Full Text] [Related]
24. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Suk KT; Kim DJ Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767 [TBL] [Abstract][Full Text] [Related]
25. Indications for the use of probiotics in gastrointestinal diseases. Girardin M; Seidman EG Dig Dis; 2011; 29(6):574-87. PubMed ID: 22179214 [TBL] [Abstract][Full Text] [Related]
26. The therapeutic effect of probiotic bacteria on gastrointestinal diseases. Sarowska J; Choroszy-Król I; Regulska-Ilow B; Frej-Mądrzak M; Jama-Kmiecik A Adv Clin Exp Med; 2013; 22(5):759-66. PubMed ID: 24285463 [TBL] [Abstract][Full Text] [Related]
27. Using probiotics and prebiotics to improve gut health. Tuohy KM; Probert HM; Smejkal CW; Gibson GR Drug Discov Today; 2003 Aug; 8(15):692-700. PubMed ID: 12927512 [TBL] [Abstract][Full Text] [Related]
28. The Future of Diabetes Management by Healthy Probiotic Microorganisms. Rad AH; Abbasalizadeh S; Vazifekhah S; Abbasalizadeh F; Hassanalilou T; Bastani P; Ejtahed HS; Soroush AR; Javadi M; Mortazavian AM; Khalili L Curr Diabetes Rev; 2017; 13(6):582-589. PubMed ID: 27758705 [TBL] [Abstract][Full Text] [Related]
29. Mind-altering with the gut: Modulation of the gut-brain axis with probiotics. Kim N; Yun M; Oh YJ; Choi HJ J Microbiol; 2018 Mar; 56(3):172-182. PubMed ID: 29492874 [TBL] [Abstract][Full Text] [Related]
30. Beneficial modulation of the gut microbiota. Walsh CJ; Guinane CM; O'Toole PW; Cotter PD FEBS Lett; 2014 Nov; 588(22):4120-30. PubMed ID: 24681100 [TBL] [Abstract][Full Text] [Related]
31. Intestinal dysbiosis and probiotic applications in autoimmune diseases. de Oliveira GLV; Leite AZ; Higuchi BS; Gonzaga MI; Mariano VS Immunology; 2017 Sep; 152(1):1-12. PubMed ID: 28556916 [TBL] [Abstract][Full Text] [Related]
32. Gut microbial metabolism and colon cancer: can manipulations of the microbiota be useful in the management of gastrointestinal health? Belcheva A; Irrazabal T; Martin A Bioessays; 2015 Apr; 37(4):403-12. PubMed ID: 25601287 [TBL] [Abstract][Full Text] [Related]
33. Microbiota and neurologic diseases: potential effects of probiotics. Umbrello G; Esposito S J Transl Med; 2016 Oct; 14(1):298. PubMed ID: 27756430 [TBL] [Abstract][Full Text] [Related]
34. The Immunomodulatory Properties of Extracellular Vesicles Derived from Probiotics: A Novel Approach for the Management of Gastrointestinal Diseases. Molina-Tijeras JA; Gálvez J; Rodríguez-Cabezas ME Nutrients; 2019 May; 11(5):. PubMed ID: 31075872 [TBL] [Abstract][Full Text] [Related]
35. Probiotics and the gut microbiota in intestinal health and disease. Gareau MG; Sherman PM; Walker WA Nat Rev Gastroenterol Hepatol; 2010 Sep; 7(9):503-14. PubMed ID: 20664519 [TBL] [Abstract][Full Text] [Related]
36. To engraft or not to engraft: an ecological framework for gut microbiome modulation with live microbes. Walter J; Maldonado-Gómez MX; Martínez I Curr Opin Biotechnol; 2018 Feb; 49():129-139. PubMed ID: 28866242 [TBL] [Abstract][Full Text] [Related]
37. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Prakash S; Rodes L; Coussa-Charley M; Tomaro-Duchesneau C Biologics; 2011; 5():71-86. PubMed ID: 21847343 [TBL] [Abstract][Full Text] [Related]
38. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids. Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376 [TBL] [Abstract][Full Text] [Related]
39. Antibiotic and Modulation of Microbiota: A New Paradigm? Rizzatti G; Ianiro G; Gasbarrini A J Clin Gastroenterol; 2018; 52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017():S74-S77. PubMed ID: 29912755 [TBL] [Abstract][Full Text] [Related]
40. Gut microbiota and probiotics intervention: A potential therapeutic target for management of cardiometabolic disorders and chronic kidney disease? Cavalcanti Neto MP; Aquino JS; Romão da Silva LF; de Oliveira Silva R; Guimarães KSL; de Oliveira Y; de Souza EL; Magnani M; Vidal H; de Brito Alves JL Pharmacol Res; 2018 Apr; 130():152-163. PubMed ID: 29410236 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]